Follow Healthline   |   Healthline on TwitterTwitter   |   Healthline on FacebookFacebook
Symptom Search   |   Treatment Search   |   Doctor Search   |   Drug Search

Drug Notebook

FDA Alerts

    Positive ANA Titer
  • Prolonged use often results in development of positive antinuclear antibody (ANA) titers.
  • Symptoms of systemic lupus erythematosus (SLE)-like syndrome may or may not accompany ANA titers.
  • Assess benefits versus risks of continued therapy if positive ANA titer develops.

    Mortality
  • Excessive mortality or nonfatal cardiac arrest rate (7.7%) in encainide- or flecainide-treated patients with asymptomatic non-life-threatening ventricular arrhythmias (with MI history >6 days but <2 years) in NHLBI's long-term CAST study relative to placebo.
  • Applicability of CAST findings to other populations (e.g., those without recent MI) uncertain.
  • Because of procainamide's proarrhythmic properties and lack of evidence of improved survival for any antiarrhythmic drug, reserve procainamide for life-threatening ventricular arrhythmias.

    Blood Dyscrasias
  • Agranulocytosis, bone marrow depression, neutropenia, hemoplastic anemia, and thrombocytopenia occur in approximately 0.5% of procainamide-treated patients, usually at recommended dosages.
  • Potentially fatal (e.g., in 20–25% of agranulocytosis cases).
  • Usually noted during the initial 12 weeks of therapy.
  • Perform CBCs, including leukocyte, differential, and platelet counts, at weekly intervals for the first 3 months of therapy and periodically thereafter.
  • Perform CBC promptly if any sign of infection (e.g., fever, chills, sore throat, stomatitis), bruising, or bleeding develops.
  • Discontinue procainamide if any of these hematologic disorders develops.
  • Blood cell counts usually return to normal 1 month after procainamide discontinuance.
  • Exercise caution in preexisting marrow failure or cytopenia of any type.

Media Gallery
Drug Info Tools
Search by color, shape and markings. click here
Check any 2 drugs for interactions. click here
Compare any two drugs side by side. click here
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
procainamide
(proe kane A mide)
LOGO 2345 LOGO 2345 | 250 mgLOGO 2345 LOGO 2345   250 mg
bottle, 100 each Procainamide HCl 250mg, Oral capsule, yellow, oblong-shaped, side 1:LOGO 2345 LOGO 2345
LOGO 2346 LOGO 2346 | 375 mgLOGO 2346 LOGO 2346   375 mg
bottle, 100 each Procainamide HCl 375mg, Oral capsule, orange, white, oblong-shaped, side 1:LOGO 2346 LOGO 2346
LOGO 2347 LOGO 2347 | 500 mgLOGO 2347 LOGO 2347   500 mg
bottle, 100 each Procainamide HCl 500mg, Oral capsule, orange, yellow, oblong-shaped, side 1:LOGO 2347 LOGO 2347
LOGO 2345 LOGO 2345 | 250 mgLOGO 2345 LOGO 2345   250 mg
bottle, 100 each Procainamide HCl 250mg, Oral capsule, yellow, oblong-shaped, side 1:LOGO 2345 LOGO 2345
PPP 757 PPP 757 | 500 mgPPP 757 PPP 757   500 mg
bottle, 100 each Procainamide HCl 500mg, Oral capsule, orange, yellow, oblong-shaped, side 1:PPP 757 PPP 757
PPP 431 | 250 mgPPP 431   250 mg
bottle, 100 each Procainamide HCl 250mg, Oral tablet, yellow, oblong-shaped, side 1:PPP 431
PPP 438 | 500 mgPPP 438   500 mg
bottle, 100 each Procainamide HCl 500mg, Oral tablet, red, oblong-shaped, side 1:PPP 438
Back to Top